Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding
- PMID: 11547718
- DOI: 10.1056/NEJMoa003223
Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding
Abstract
Background: After an episode of acute bleeding from esophageal varices, patients are at high risk for recurrent bleeding and death. We compared two treatments to prevent recurrent bleeding--endoscopic ligation and combined medical therapy with nadolol and isosorbide mononitrate.
Methods: We randomly assigned 144 patients with cirrhosis who were hospitalized with esophageal variceal bleeding to receive treatment with endoscopic ligation (72 patients) or the combined medical therapy (72 patients). Sessions of ligation were repeated every two to three weeks until the varices were eradicated. The initial dose of nadolol was 80 mg orally once daily, with adjustment according to the resting heart rate; isosorbide mononitrate was given in increasing doses, beginning at 20 mg once a day at bed time and rising over the course of one week to 40 mg orally twice a day, unless side effects occurred. The primary end points were recurrent bleeding, complications, and death.
Results: The median follow-up period was 21 months. A total of 35 patients in the ligation group and 24 in the medication group had recurrent bleeding. The probability of recurrence was lower in the medication group, both for all episodes related to portal hypertension (P=0.04) and for recurrent variceal bleeding (P=0.04). There were major complications in nine patients treated with ligation (seven had bleeding esophageal ulcers and two had aspiration pneumonia) and two treated with medication (both had bradycardia and dyspnea) (P=0.05). Thirty patients in the ligation group died, as did 23 patients in the medication group (P=0.52). The probability of recurrent bleeding was lower for patients with a hemodynamic response to therapy, defined as a decrease in the hepatic venous pressure gradient of more than 20 percent from the base-line value or to less than 12 mm Hg (18 percent, vs. 54 percent in patients with no hemodynamic response at one year; P<0.001), and the probability of survival was higher (94 percent vs. 78 percent at one year, P=0.02).
Conclusions: Combined therapy with nadolol and isosorbide mononitrate is more effective than endoscopic ligation for the prevention of recurrent bleeding and is associated with a lower rate of major complications. A hemodynamic response to treatment is associated with a better long-term prognosis.
Comment in
-
Prevention of recurrent variceal bleeding.N Engl J Med. 2002 Jan 17;346(3):209-10. doi: 10.1056/NEJM200201173460315. N Engl J Med. 2002. PMID: 11796860 No abstract available.
-
Nadolol and isosorbide prevented recurrent variceal bleeding better than did endoscopic ligation in cirrhosis.ACP J Club. 2002 May-Jun;136(3):94. doi: 10.7326/acpjc-2002-136-3-094. ACP J Club. 2002. PMID: 11985435 No abstract available.
Summary for patients in
-
Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrates to prevent recurrent variceal bleeding.Gastrointest Endosc. 2002 May;55(6):761-4. Gastrointest Endosc. 2002. PMID: 12085777 No abstract available.
Similar articles
-
Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding.N Engl J Med. 1996 Jun 20;334(25):1624-9. doi: 10.1056/NEJM199606203342502. N Engl J Med. 1996. PMID: 8628357 Clinical Trial.
-
Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP).Lancet. 1996 Dec 21-28;348(9043):1677-81. doi: 10.1016/s0140-6736(96)05406-2. Lancet. 1996. PMID: 8973428 Clinical Trial.
-
Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial.Gut. 2009 Aug;58(8):1144-50. doi: 10.1136/gut.2008.171207. Epub 2009 Feb 12. Gut. 2009. PMID: 19218249 Clinical Trial.
-
The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage.P R Health Sci J. 2000 Mar;19(1):57-67. P R Health Sci J. 2000. PMID: 10761206 Review.
-
Cirrhotic portal hypertension: current and future medical therapy for primary and secondary prevention of variceal bleeding.Minerva Med. 2006 Aug;97(4):325-45. Minerva Med. 2006. PMID: 17008837 Review.
Cited by
-
Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients.Dig Dis Sci. 2005 Aug;50(8):1538-47. doi: 10.1007/s10620-005-2877-1. Dig Dis Sci. 2005. PMID: 16110851 Clinical Trial.
-
Management of portal hypertension.Postgrad Med J. 2004 Nov;80(949):634-41. doi: 10.1136/pgmj.2004.020446. Postgrad Med J. 2004. PMID: 15537846 Free PMC article. Review.
-
Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats.Front Physiol. 2019 Sep 20;10:1169. doi: 10.3389/fphys.2019.01169. eCollection 2019. Front Physiol. 2019. PMID: 31607942 Free PMC article.
-
Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.Semin Intervent Radiol. 2005 Dec;22(4):278-86. doi: 10.1055/s-2005-925554. Semin Intervent Radiol. 2005. PMID: 21326706 Free PMC article.
-
Pediatric gastrointestinal bleeding: Perspectives from the Italian Society of Pediatric Gastroenterology.World J Gastroenterol. 2017 Feb 28;23(8):1328-1337. doi: 10.3748/wjg.v23.i8.1328. World J Gastroenterol. 2017. PMID: 28293079 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical